Advertisement

Archives of Pharmacal Research

, Volume 29, Issue 2, pp 178–182 | Cite as

Crystal form of cephradine

  • Young Taek Sohn
  • Sun Hee Park
Articles Drug Efficacy

Abstract

Four crystal forms of cephradine were isolated by recrystallization and characterized by powder X-ray diffractometry, differential scanning calorimetry, and thermogravimetric analysis. The dissolution patterns of four crystal forms of cephradine were studied in water at 37±0.5°C, 90 rpm for 120 min. The amount dissolved at 120 min was highest for Form I (100%), followed by Form 3 (98.9%), Form 4 (77.83%), and Form 2 (75.55%). After storage for two months at 0% RH (silica gel, 20°C), 52% RH (saturated solution of Na2Cr2O7·2H2O/20°C), and 95% RH (saturated solution of Na2HPO4/20°C), none of the crystal forms showed transformation.

Key words

Cephradine Crystal form Polymorphism Solubility Transformation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Giron, D., Thermal analysis and calorimetric methods in the characterization of polymorphs and solvates.Thermochim. Acta, 248, 1–59 (1995).CrossRefGoogle Scholar
  2. Grünenberg, A., Polymorphie und thermische analyse pharmazeutischer Wirkstoffe.Pharmazie in unserer Zeit, 26, 224–231 (1997).PubMedCrossRefGoogle Scholar
  3. Haleblian, J. K., Characterization of habits and crystalline modification of solids and their pharmaceutical applications.J. Pharm. Sci., 64, 1269–1288 (1975).PubMedCrossRefGoogle Scholar
  4. Haleblian, J. K. and McCrone, W. C., Pharmaceutical applications of polymorphism.J. Pharm. Sci., 58, 911–929 (1969).PubMedCrossRefGoogle Scholar
  5. Higuchi, W.I., Lau, P. K., Higuchi, T., and Shell, J. W., Polymorphism and drug availability, solubility relations in the methylprednisolone system.J. Pharm. Sci., 52, 150–153 (1963).PubMedCrossRefGoogle Scholar
  6. Hüttenrauch, R., Fundamentals of Pharmaceutics.Acta Pharm. Technol., 34, 1–10 (1988).Google Scholar
  7. Kuhnert-Brandstätter, M., Polymorphie von Arzneistoffen und ihre Bedeutung in der pharmazeutischen Technologie.Informationsdienst A.P.V., 19, 73–90 (1973).Google Scholar
  8. Kuhnert-Brandstätter, M. and Lehner, G., Differentialthermoanalyse und IR-spektroskopische untersucungen von arzneistoffen, die als hydrate vorliegen.Sci. Pharm., 52, 267–279 (1984).Google Scholar
  9. Shefter, E. and Higuchi, T., Dissolution behavior of crystalline solvated and nonsolvated forms of some pharmaceuticals.J. Pharm. Sci., 52, 781–791 (1963).PubMedCrossRefGoogle Scholar
  10. Sohn, Y. T., Effect of crystal form on bioavailability,J. Kor. Pharm. Sci., 34, 443–452 (2004).CrossRefGoogle Scholar
  11. Sohn, Y. T., Rhee, J. K., and Im, W. B., Polymorphism of Clarithromycin.Arch. Pharm. Res., 23, 381–384 (2000).PubMedCrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2006

Authors and Affiliations

  1. 1.College of PharmacyDuksung Women’s UniversitySeoulKorea

Personalised recommendations